✦ LIBER ✦

Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B

✍ Scribed by Robert G. Gish; Anna S. Lok; Ting–Tsung Chang; Robert A. de Man; Adrian Gadano; José Sollano; Kwang–Hyub Han; You–Chen Chao; Shou–Dong Lee; Melissa Harris; Joanna Yang; Richard Colonno; Helena Brett–Smith

Book ID: 119760012
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 303 KB
Volume: 133
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2007.08.025

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

645 VIROLOGICAL RESPONSE AT 12 WEEKS OF

645 VIROLOGICAL RESPONSE AT 12 WEEKS OF ENTECAVIR THERAPY PREDICTS HBeAg CLEARANCE IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS

✍ B.-C. Song; H.B. Chae; Y.N. Kim; B.S. Lee; Y.-K. Cho 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Results of up to 2 years of entecavir vs

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

✍ T.-T. Chang; Y.-C. Chao; V. V. Gorbakov; K.-h. Han; R. G. Gish; R. De Man; H. Ch 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

Entecavir treatment for up to 5 years in

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB 👁 2 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E

Prediction of response to entecavir ther

Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels

✍ J. W. Shin; S. W. Jung; B. R. Park; C. J. Kim; J. B. Eum; B. G. Kim; I. D. Jeong 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

Efficacy of 96 weeks adefovir dipivoxil

Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic hepatitis B patients with various baseline biochemical levels

✍ L. Zhuang; J. You; L. Kong; H. Lei; R.-D. Yang; X. Zhang; Q.-Q. Wang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Entecavir shows limited efficacy in HBeA

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy

✍ Jurriën G.P. Reijnders; Suzan D. Pas; Martin Schutten; Robert A. de Man; Harry L 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 398 KB